-+ 0.00%
-+ 0.00%
-+ 0.00%

B of A Securities Initiates Coverage On Avalo Therapeutics with Buy Rating, Announces Price Target of $35

Benzinga·06/12/2026 09:54:52
Listen to the news
B of A Securities analyst Alec Stranahan initiates coverage on Avalo Therapeutics (NASDAQ:AVTX) with a Buy rating and announces Price Target of $35.